Flow Neuroscience AB

Flow Neuroscience AB, based in Sweden, develops non-invasive brain stimulation technology aimed at treating depression through its flagship product, the Flow headset, which utilizes transcranial Direct Current Stimulation (tDCS). Flow Neuroscience AB was founded in 2016 and operates out of Malmö, Sweden, focusing on mental health solutions. The company was co-founded by Daniel Månsson and Erik Rehn and is led by CEO Erin Lee. Flow Neuroscience has successfully completed 5 funding rounds, including its latest Series A round in which it raised EUR 7.

9 mn from lead investor Khosla Ventures and others including Global Brain, Kirin Holdings Company, Limited. , SOSV, Schox Patent Group, and SwissHealth Ventures. The total amount raised by the company to date is EUR 7. 9 mn.

Flow Neuroscience specializes in non-invasive brain stimulation technology for treating depression, utilizing a device known as the Flow headset, which employs transcranial Direct Current Stimulation (tDCS). This product targets adults with mild to severe depression and can be used both in clinical settings and at home. Their market presence extends to the United Kingdom, various European Union countries, Norway, Hong Kong, and Brazil, supported by partnerships with NHS services and healthcare providers. Flow Neuroscience serves both individual users and healthcare professionals recommending the headset as a complementary therapy for depression management.

In the most recent year of 2022, Flow Neuroscience reported a revenue of EUR 767,671. 20, with an EBITDA of EUR -3,789,201. 60. Flow Neuroscience plans to leverage its recent funding to develop new products aimed at enhancing its offerings in mental health treatment.

The company is exploring expansion into new geographic markets to increase its reach, although specific regions and timelines for these expansions have not yet been disclosed. The recent investment from naturalX Health Ventures is expected to support these growth initiatives.